purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation elan earnings call period ending march image source motley fool elanco animal health elan q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorladies gentleman thank standing welcome everyone elanco animal health firstquarter earnings conference call time line placed mute prevent background noise speaker remark questionandanswer session operator instruction thank would like hand call katy grissom head investor relation may begin conferencekaty grissom head investor relation good morning thank joining u elanco animal health firstquarter earnings call katy grissom head investor relation joining call today jeff simmons president chief executive officer todd young chief financial officer scott purucker investor relation slide referenced call available investor relation section elancocom today discussion include forwardlooking statement statement based current assumption expectation subject risk uncertainty could cause actual result differ materially forecast information see risk factor discussed today earnings press release well latest form k q filed secwe undertake duty update forwardlooking statement remark today focus nongaap financial measure reconciliation nongaap measure included appendix today slide earnings press release prepared remark happy take question turn call jeff jeff simmons president chief executive officer thanks katy good morning everyone elanco poised exciting strong business momentum continued first quarter reinforced diversity portfolio geographic result quarter exceeded top end guidance range key metric revenue adjusted ebitda adjusted eps encouraged strong progress latestage pipeline advanced significantly last several month one elanco approach collaboration decisionmaking driving positive productive outcome across world energy resiliency creativity filling hall permeating conversation customer focus year remains growth innovation cash many proof point start year beginning slide underlying business encouraging start may remember quarterly result first half last year impacted shift customer purchasing related erp system integration second quarter first quarter determined last year estimate shift million million focus comment underlying growth excluding estimated impact shift first quarter underlying revenue growth continued mid singledigit range estimated first quarter building constantcurrency growth third fourth quarter last year remain confident latestage innovation based dialogue fda status package submitted increased certainty expected approval timing bovaer zenrelia credelio quattro continue expect bring differentiated product market revenue contribution expected three product second half year cash quarter reduced net debt improved operating cash flow nearly million year year result disciplined focus improving net working capital benefit completing erp system integration reduced balance sheet inventory even built inventory new product continue expect sale aqua business close around midyear finally increasing expectation constantcurrency revenue growth full year growth updating key guidance metric reflect unfavorable impact increased strength yous dollar since february constantcurrency expectation improving adjusted ebitda adjusted eps moving slide review business performance first quarter delivered revenue billion side business performing well first quarter pet health estimate constantcurrency underlying growth globally includes approximately underlying revenue growth yous improved supply increased innovation sale partially offset competitive macro headwind reduced consumer activity result adverse weather felt industry january expected dispensing improved sequentially february march see momentum also carrying second quarter otc retail business performing well based market analysis retail channel advantage classic brand dog cat top growth brand quarter portfolio benefited increased physical availability higherthanexpected overall market share advantage family retail channel addition encouraged seresto investment new bold dtc advertising campaign season drove fivepoint improvement unaided awareness brand important leading indicator share growth broadly across otc portfolio leveraging market leadership drive growth implementing key initiative instore online across brand retailer enter heart north american parasiticide season yous vet clinic market visit continue pressured primarily result labor capacity constraint despite impact continued competitive innovation consistent execution strategy strengthening elancos position driving line betterthanexpected market share performance expanded vet sale force significantly increased share voice important leading indicator expected lift portfolio year progress additionally innovation elevating relevance portfolio focused enhancing partnership strategic corporate account also investing key platform used veterinarian canine parvovirus monoclonal antibody cpma continues ramp sale improving sequentially month start year late april launched new marketing campaign geared toward pet owner veterinarian raise awareness virus spread effectiveness elancos breakthrough treatment effort include firstever online parvo tracking tool empowering pet owner veterinary community gamechanging intelligence help keep puppy safe expanded supply capacity enhancing targeting effort drive penetration early data show clinic product freezer outcome puppy pet owner clinic staff improved leading reordering expect continued ramp product throughout year moving international pet health estimate underlying constantcurrency revenue growth approximately first quarter yearoveryear basis line expectation growth driven improved demand otc parasiticide product led seresto certain european market including spain additionally continue see increased demand credelio family strong ramp adtab europe meaningfully investing launch adtab including pointofsale well digital traditional directtoconsumer advertising permitted otc product region employing principle yous strategic focus physical availability share voice driving strong launch curve limited cannibalization existing leading portfolio collar topicals europe shifting farm animal globally estimate underlying constantcurrency revenue growth yous approximately underlying growth driven poultry cattle poultry benefited rotation extended use product quarter going forward year expect increased use ionophores market continues shift antibiotic ever program antibiotic important human medicine program cattle slight uptick cattle feed march continue see increased day feed broadly benefiting medicated feed additive portfolio beef medicated feed additive cornerstone elancos diverse farm animal portfolio innovation enabling u gain market share opportune time continue pleased trajectory experior yous continued adoption expected increased use heifer yous well strength canada giving u increased confidence product approach blockbuster status globally demand elancos livestock sustainability portfolio experior anticipation bovaer driving sale growth rumensin across beef dairy insulating one largest brand finally farm animal business outside yous estimate decline approximately continued demand growth poultry offset volatility china notably swine continue take cautious approach regard expectation china year overall first quarter global business launched innovation base portfolio growth driver delivered raised expectation fullyear constantcurrency revenue growth contribution latestage pipeline moving slide made progress across innovation portfolio productivity strategy first quarter portfolio saw price growth core business continues stabilize regarding productivity operating cash flow improved first quarter restructuring aqua divestiture progressing planned let u get innovation starting slide late shared expectation deliver highimpact innovation market last three year delivered innovation addition numerous regional product life cycle management improvement importantly remain track generate expected million million revenue new product innovation moving slide launched new product led experior nutriquest adtab credelio plus credelio cat performing line better expectation portfolio delivered million doubling today introducing new quarterly disclosure innovation sale first quarter new product sale contributed million expect basket product deliver million million year excluding contribution latestage pipeline encouraged contribution innovation already market thrilled next phase historic launch window right front u shared previously yous regulatory process rolling iterative productive engagement fda center veterinary medicine last several year specifically last several month three key latestage program since started submission product late majority technical section subsection approved agency continue confident approvability differentiated product moving slide zenrelia credelio quattro progressed since february believe fda data necessary complete review product product expect technical section including label approved fda end june approval technical section new animal drug application nada undergoes expected day final administrative review putting full approval expectation q little product specifically zenrelia jak inhibitor targeting control pruritus atopic dermatitis dog least month age remain confident product differentiated current market option market research show clear interest desire additional option continue prioritize optimization label provide meaningful differentiation expect efficient approvaltolaunch window targeting product market end third quarter additionally expect approval zenrelia several international market starting late fastest globalization effort ever moving credelio quattro broadspectrum parasiticide targeting coverage fleet tick heartworms internal parasite single monthly dose shared previously expect quattro differentiated incumbent product market broader coverage specifically expect coverage tape worm including known zoonotic posing risk human effectively prevented eliminating fleet expect broader coverage ability prevent heartworms first monthly dose seeking demonstrate fda position credelio quattro uniquely market quattro targeting launch fourth quarter year finally bovaer firstinclass methanereducing feed ingredient yous dairy market final stage review fda completion expected end may appreciate fda commitment maintaining high standard risk sciencebased review balancing need quickly bring solution market regulatory process bovaer underscore need fda innovation agenda modernize regulatory process continuing help shape ecosystem inset carbon market support progression toward opportunity climateneutral farming also creating revenue stream dairy farm across country several large cpg company indicated interest partnering dairy milk coop reduce onfarm greenhouse gas emission supply chain expected yous clearance bovaer mark significant milestone opening next major market opportunity animal health livestock sustainability look forward integrating bovaer portfolio expect begin selling product third quarter three latestage product blockbuster potential meaningful elancos growth opportunity near medium term expected drive adjusted ebitda growth time based launch timing shared today expected ramp curve peak sale three product continue support goal million million innovation revenue continued growth expected second half decade exciting quarter ahead u product approval launch perspective meanwhile ellen de brabander team remain focused advancing phase pipeline refilling early stage project progressing laterstage program continue believe il monoclonal antibody canine dermatology approved progressing many differentiated asset research development continue see robust pipeline supporting ambition deliver consistent highimpact innovation pas todd provide firstquarter result financial guidancetodd young chief financial officer thank jeff good morning everyone today focus comment firstquarter adjusted measure please refer today earnings press release detailed description yearoveryear change reported result starting slide first quarter delivered billion revenue reported constantcurrency decline price contributed quarter jeff referenced yearoveryear comparison first quarter impacted erp system blackout occurred last year estimated sale million million shifted second quarter first quarter reflecting percentage point detriment growth first quarter year limited impact foreign exchange rate estimate underlying business grew slightly ahead expectation estimated impact noted slide business area pet health constantcurrency decline estimated headwind yearoveryear growth percentage point erp blackout yous pet health revenue declined including headwind yearoveryear growth approximately percentage point erp blackout return underlying growth driven price resupply certain vaccine stock last year onetime benefit related moving certain legacy bayer product distribution sale new product quarter business also faced headwind weatherimpacted january competitive innovation lower vet visit outside yous pet health business declined constant currency estimated headwind yearoveryear growth approximately percentage point erp blackout underlying growth quarter driven return normalized demand pattern spain ramp innovation product led adtab higher demand credelio family product seresto across europe globally farm animal business declined constant currency estimated headwind yearoveryear growth percentage point erp blackout yous farm animal business grew estimated headwind yearoveryear growth approximately percentage point erp blackout growth underlying business driven expanded experior adoption vaccine resupply demand elanco poultry product outside yous farm animal business declined constant currency estimated headwind yearoveryear growth approximately percentage point erp blackout decline underlying business driven weakness asian swine market partially offset increased demand poultry europe majority yearoveryear decline aqua business result erp blackout continuing income statement slide gross margin declined basis point line expectation estimated impact yearoveryear growth gross margin erp blackout basis point sale highmargin legacy bayer animal health product realized first quarter remaining decline driven approximate basispoint headwind slowing manufacturing output work reduce balance sheet inventory inflation partially offset price growth operating expense increased year year quarter rd expense increased million primarily driven employeerelated expense timing project expense sga expense grew primarily driven expanded yous pet sale force increased promotional activity across targeted pet health brand employeerelated expense partially offset itrelated saving result consolidating one erp system interest expense million compared million last year additionally expense declined million first quarter last year million year driven simplified operation certain volatile market including argentina moving slide adjusted ebitda million quarter yearoveryear comparison negatively impacted estimated million million benefit erp blackout first quarter last year underlying business decline driven higher sale offset decision increase commercial investment drive longterm revenue growth pet health adjusted eps quarter yearoveryear comparison negatively impacted estimated benefit erp blackout first quarter last year slight increased underlying performance primarily driven favorable tax rate moving guidance let offer word cash debt working capital slide cash operation million quarter million yearoveryear improvement operating cash flow reflects improvement inventory saving reduction project spend completion bayer erp integration ended quarter net debt billion paid million debt enabled improvement operating investing cash flow end march net leverage ratio time trailing month ebitda negatively impacted erp blackout last year drove estimated turn increase continue expect million million free cash flow available debt paydown year anticipate yearend net leverage ratio time considering expected debt paydown net proceeds aqua divestiture continue expect net proceeds billion billion intend use primarily debt paydown leading expected net debt adjusted ebitda ratio mid four time range end year let u move financial guidance starting slide full year tightening guidance range reflect firstquarter outperformance impact strengthening yous dollar raising bottom end constantcurrency revenue growth updating adjusted ebitda adjusted eps reflect fx rate early may reminder guidance include contribution anticipated latestage pipeline product account expected impact aqua divestiture slide provide detail updated revenue expectation raised constantcurrency growth primarily driven yous farm animal international pet health business higher innovation sale base portfolio improved outlook also account expected reduced sale kexxtone european cattle product paused sale product manufacturing process review ema expect fullyear impact approximately million revenue million adjusted ebitda compared february guidance regarding fx expect million headwind full year million higher february guidance slide provide bridge adjusted ebitda adjusted eps compared february guidance expect adjusted ebitda million billion inclusive incremental million headwind unfavorable impact foreign exchange rate excluding fx impact increasing bottom end adjusted ebitda guidance million top end million improved constantcurrency assumption reflect q overperformance increased confidence full year adjusted eps raising expectation full year despite unfavorable fx result q overperformance compared february guidance improvement interest expense tax slide appendix provides update several additional assumption slide provide financial guidance second quarter expect revenue billion billion adjusted ebitda million million adjusted eps shared last year first quarter result erp system blackout approximately million revenue million adjusted ebitda adjusted eps shifted first quarter second quarter impact reported growth rate second quarter shown slide estimated headwind yearoveryear revenue growth erp blackout first quarter unwind contributing approximately percentage point secondquarter revenue growth excluding estimated impact erp blackout expect underlying constantcurrency revenue growth shift also expected positively impact yearoveryear growth adjusted ebitda adjusted eps second quarter shown slide line result first quarter ebitda expectation reflect manufacturing headwind slowing plant increased investment pet health business overall executing ahead initial expectation year look forward delivering opportunity launch exciting new product later year hand back jeff closing commentsjeff simmons president chief executive officer thanks todd exciting time elanco momentum across business global team highly engaged intensely focused deeply committed building positive trajectory set past three quarter strategic action taken sharpen focus invest commercial growth driver delivering result focus consistent highimpact innovation driving immense progress two potential blockbuster experienced cpma already market three expected coming month il product slated next year track deliver meaningful growth innovation sale next several year enter pivotal moment elancos trajectory stability within leadership team consistency strategy paying base business growing operating cash flow improving contribution new product exceeding expectation factor combined durability diverse portfolio balanced geographic presence give u confidence increase expectation constantcurrency growth full year elanco track deliver strong look forward continuing engage throughout year turn katy moderate qakaty grissom head investor relation thanks jeff would like take question many caller possible ask limit one question one followup operator please provide instruction qa session take first caller question answer operatorthank time begin questionandanswer session operator instruction pause moment compile qa rosterkaty grissom head investor relation go ahead take first questionoperatorthank first question come line jon block stifel please go aheadjon block stifel financial corp analyst great guy thanks good morning jeff interesting comment otc para market think market weak consumer seemingly pressure sometimes pressure cause trade want make sure understand seem like gaining share within market performance even normalize stocking commentary maybe elaborate ask followup zenrelia look like going compress launch timing initially called two four month seems like going move something shorter changed change talk u confidence think launch timing internationally zenrelia well thanks timejeff simmons president chief executive officer yeah thanks jon let start second question first zenrelia looking technical section approved said second quarter administrative process day typically would go third quarter know said clearly production line process zenrelia much fit product like parasiticides made facility preparing product manufactured ready course wait labeling believe created additional efficiency time approval launch current expectation bring product market actually q current plan relative otc real quickly fundamentally yes see strong demand otc product market quite resilient even midst dynamic also think see little bit continuum pull back innovation entered market inside vet clinic seeing robust demand kind coming back otc product portfolio strong put strategy work think driving lot expanded physical availability club dollar grocery share voice think really want point seresto seen probably jump brand awareness seresto since owning product owning bayer seen unaided awareness lot bolder campaign mentioned comment constantly optimizing price volume overall innovation classic brand yous even want note adtab one fastest ramping product europe retail market look think specific question saw weather impact overall seen tradedown occur otc space portfolio handle trade well premium product portfolio playing seen pretty nice jump back january weather took seen sequential improvement saw increase march actually see momentum carrying second quarter omnichannel approach took purchased bayer paying strategy bobby ramiro place paying continue see diversity really nice tailwind go vet clinic market launching new productsjon block stifel financial corp analyst thank youoperatorthank next question come line erin wright morgan stanley please go aheaderin wright morgan stanley analyst great thanks remind u ask two upfront little bit related remind u embedded guidance relates expense associated upcoming blockbuster launch sort increased certainty around launch change thinking investment making ahead launch second would conversation fda changed next milestone give sort clarity launch timing instance could actually see approval timeline would change launch timeline thankstodd young chief financial officer erin thanks question launch side feel good timing laid today team preparing training sale force preparing marketing material ready go time biggest cost really tv ad running tv ad included expense guide like included sale bovaer zenrelia credelio quattro guide continue believe ebitdapositive relative guidance laid today turn back jeff fda questionjeff simmons president chief executive officer yeah erin might broaden question little bit get think really important know innovation blockbuster product specifically zenrelia credelio important u let add little framing comment made opened call first pleased progress made key asset since february actually lot progress happened driven increased certainty move closer end approval process yes dialogue fda rolling iterative productive engagement erin fair constructive frequent really last several month responding question agency common believe animal drug user fee act adufa working specific asset constructive changed changed since february changed many section subsection submission approved product progressed simply though backandforth interaction taken slightly time estimated path firsthalf approval thus moving final day administrative review third quarter think importantly increased certainty timing interaction mentioned think also important say changed changed continue expect product differentiated versus current offering still expect technical section including label approved first half end june expect revenue contribution still expected second half two product well bovaer importantly believe fda need approval launch planning question marketing well underway yous pet health well positioned right believe need relative launch competitive ever good nice lead indicator engagement score yous pet health high probably year highest think global company nice lead indicator preparedness ready launch soon possible noted expect right q zenrelia q credelio quattrokaty grissom head investor relation thanks take next questionoperatorthank next question come line michael ryskin bank america please go aheadmike ryskin bank america merrill lynch analyst great thanks taking question congrats quarter update ask time well following new product approval especially zenrelia quattro transparent u term timing approval launch term expectation label differentiation thing like get closer expected date seeing change marketplace existing player zoetis derm zoetis eye simparica trio nexgard plus anything build inventory different conversation distributor vet wondering sort market going entering evolving approach sort golive date q qand followup little bit quicker hope going kexxtone eu update provided seems like pretty meaningful flowthrough obviously seems like sort cutting could give u little bit color exactly happened eu chance come back point sort look forward next six month thanksjeff simmons president chief executive officer yeah good question john thank youkaty grissom head investor relation mike mikejeff simmons president chief executive officer excuse mike sorry mikemike ryskin bank america merrill lynch analyst thanks katyjeff simmons president chief executive officer sorry listen mike real quick look anticipate see competitive reaction marketplace marketplace seen lot innovation come made lot decision last couple year relative launch taken seriously new preparing time lot product testing building muscle launch zorbium bexacat parvo would say really well prepared look think first thing would emphasize come back couple basic share voice create clinic awareness lead clinic penetration added sale force share voice metric high grown dramatically last two quarter key lead indicator looking know important credible experienced people lot deep relationship territory key number one look differentiation working optimize label know differentiation also impact adoption also would note fourpillar approach talked derm u really help help quattro also help zenrelia existing portfolio able say therapeutic vaccine derm parasiticides point thing well kind calling nextgeneration sale launch digital campaign thing would note derm accretive u new big market excited zenrelia also excited il coming look thing look derm market large growing meaningfully international yous even last quarter expect differentiated zenrelia market research continues indicate vet looking option key fourth pillar u offering believe put u really good place mentioned engagement high going back earlier question zenrelia globally positioned see zenrelia come marketplace believe late year international market fastest global launch ever little bit launch side jumping kexxtone kexxtone key cattle product europe controlledrelease capsule treat ketosis rumen cattle manufacturing process key product taken product market focus ema believe manufacturing team working hard manufacturing process see product coming back market anticipate probably late felt prudent highlight product removal markettodd young chief financial officer mike impact gross margin also inventory writeoffs wellkaty grissom head investor relation thanks take next questionoperatorthank next question come line balaji prasad barclays please go aheadkaty grissom head investor relation balaji look like hearing let u go next caller get back queueoperatorcertainly next question come line umer raffat evercore please go aheadmike difiore evercore isi analyst hi good morning guy mike difiore umer thanks much taking question two ask first one first regarding bundling consistently said derm asset portfolio greatly enhance bundling capability therefore enhance competitiveness pet health question bundling discussion happened yet need wait launch pricing kind get established mean mentioned prepared remark continue solidify partnership corporate account followupjeff simmons president chief executive officer yeah mike exactly right mean quite common marketplace vet practice whether corporate general practitioner going carry certain number product bring wider portfolio company going help across board fundamental kind principle play matter size clinic get group larger corporately question another alternative derm side going help overall market research show high interest two principle play mike see happening today high desire going forwardtodd young chief financial officer yeah mike provide incentive customer based volume purchase u able purchase derm u give ability get saving also incentive buy product u increase volume really incentive structure talking full portfolio one four major company yous vet sidemike difiore evercore isi analyst got helpful followup question brief one may missed could quantify much onetime bayer channel stocking amounted quartertodd young chief financial officer million millionmike difiore evercore isi analyst fifteen okkaty grissom head investor relation thanks take next calleroperatorthank next question come line ekaterina knyazkova jpmorgan please go aheadekaterina knyazkova jpmorgan chase company analyst hey thank much first question bovaer remind u stand point term manufacturing capacity think capacity also implication kind think launch product second question bird flu epidemic yous thought could impact producer anything watching particularly concerned thank muchjeff simmons president chief executive officer yeah thank question bovaer manufacturing product united state ready labeled bagged ready go purchased partnering contract manufacturer europe product ready targeted q launch product relative hn continuing monitor closely work customer make sure heightened biosecurity measure think couple thing look see issue increasing last couple week pretty stable something want keep eye think producer profitability also especially dairy consumer response lead indicator keep eye emphasize overall seen see impact business result point time hnkaty grissom head investor relation great thanks take next callerekaterina knyazkova jpmorgan chase company analyst thank youkaty grissom head investor relation thanksoperatorthank next question come line brandon vazquez william blair please go aheadbrandon vazquez william blair company analyst hi everyone thanks taking question first guidance really encouraging guy put nice speed raised guidance little bit especially uncertain macro time talk far first quarter specifically kind outperforming give confidence raising guidance especially also eps line think top fx headwind still able increase penny followup quick clarification pipeline think prepared remark mentioned think get onemonth heartworm efficacy quattro confirm fda already approved clinical data looking feel comfortable get approval thank youtodd young chief financial officer hey brandon thank question q really great performance yous farm business seeing accelerating adoption experior continued growth rumensin portfolio effect talked broadbased solution customer pet side farm side bringing together continue get ability offset generic competition drive growth poultry really strong got prrs vaccine called prevacent continues well yous farm market really international pet continue see strong momentum brazil well europe adtab jeff mentioned earlier great job gaining sale across european country launch seeing le cannibalization topicals collar europe launch originally expected big driver confidence raise constantcurrency guidance eps one better cash performance expected q team done really good job focusing improving net working capital delivering cash allowed u borrow cash q typically pay corporate bonus well sort seasonal effect rebate mean pay interest borrowing rest year allows u reduce interest expense finally tax tax credit receiving state indiana allowing u little better tax expectation thought originally pick penny fullyear guide transfer jeff second half questionjeff simmons president chief executive officer yeah thank brandon relative quattro correct said early passed heartworm threshold heartworm control high parameter cbm yes making assumption onemonth control data package submitted well dialogue cbm thank youkaty grissom head investor relation thanks take next calleroperatorthank next question come line nathan rich goldman sachs please go aheadnate rich goldman sachs analyst hi good morning thanks question derm product ask upfront international approval zenrelia seems like timing may shifted little bit earlier anticipated guess detail changed certain market approval expected yearend also il monoclonal antibody know timing unchanged slide think submission made maybe quarter zenrelia difference sort time line review usda versus fda keep mind term might see product approvedjeff simmons president chief executive officer yeah thank question relative let hit il first confirmed product expected noted made nice progress since highlighting going part million million key contribution derm portfolio internationally zenrelia something working hard relative bayer came built greater presence pet presence regulatory well presence increase capability regulatory submission quicker ellens team worked hard term globalizing package customizing key country added tim bennington marketing side really able target market matter especially earlier thing come together really accelerate noted specifically imagine big pet market submission made dialogue regulatory authority confident going see product come international market q really outcome capability built last two year global regulatorynate rich goldman sachs analyst thank youkaty grissom head investor relation thanks take next calleroperatorthank next question come line david westenberg piper sandler please go aheaddave westenberg piper sandler analyst hi thanks taking question congrats quarter couple innovation front first quattro product talk little bit white space product specifically maybe kind talk category growth namely kind thinking see quattro play differentiation tapeworm broader coverage seeing taking share broad spectrum parasiticides seeing growing oldgeneration oral parasiticides kind see market taking market growth maybe topicals otc kind product secondly injectable monoclonal derm product pipeline kindred course guy inherited later something fix kind product know il could coming maybe maybe ready talk pipeline would curious think injectable derms incredibly good market potential thank youjeff simmons president chief executive officer yeah thank question great great question let start derm product yes lot work relative technology inside kindred bio happy acquisition manufacturing plant come making parvo make monoclonal antibody well continue progress pipeline noted lot detail relative highlighted longacting next generation derm product follow behind kindred portfolio play continued work noted usda asked u increase number dog number treatment actually extended timeline product specific really requirement specific relative parasiticide market great question look largest market animal health couple principle play consistently seen innovation come first innovation usually increase size market seen last couple innovation come recently believe innovation second see legacy innovation get impacted soonest rapidly seen portfolio heather well see important third one oral broader spectrum growing fastest combine three thing together believe quattro broadest coverage differentiated combined omnichannel approach inside clinic able drop ship home fourpillar approach zenrelia put quattro strong position would want broadest coverage available believe credelio brand awareness continues climb across marketplace factor play bring broadest coverage product largest animal health market second half year excited thatkaty grissom head investor relation right thanks take next oneoperatorthank next question come line steven scala td cowen please go aheadchris lobianco td cowen analyst hi chris steve scala one question technical approval aspect level risk associated fda administrative review technical group granted undertake launch promotional activity technical approval granted finally disclose technical approval granted hopefully junethank youjeff simmons president chief executive officer yes wait course final approval final approval everything public label nothing come technical section approved final approval day administrative side relative informing material news product share promptly appropriately thank youoperatorthank next question come line navann ty bnp paribas please go aheadnavann ty exane bnp paribas analyst hi good morning two question please first one innovation early discussion sale force tried discus upcoming innovation expect incrementally stronger pricing power higher relevance elancos portfolio separate question activist investor could discus dialogue interaction ancora date since appointment turner wallace board since late march thank youjeff simmons president chief executive officer thank question said launching look holistically take course know market reward innovation pet side especially take valuebased approach holistic approach looking product differentiation new innovation also portfolio todd mentioned earlier also look standpoint offering four pillar portfolio certain clinic look potentially volume opportunity take valuebased approach pricing side product relative investor investor mentioned focus come agreement publicly communicated around principle keeping energy inside company concentrated focus execute value agenda front u rationale behind decision happy continue executing go rest katy grissom head investor relation thanks take last calleroperatorthank last question day come balaji prasad barclays please go aheadbalaji prasad barclays analyst right good morning thank back couple firstly significance technical approval administrative review goal technical approval rescinded administrative review period clarify exactly happens one two parasiticide side obviously seen competitor post strong number simparica trio trying gauge part market expansion market dislocation seen within parasiticides market kind linked incremental color label expectation discussion fda thank youjeff simmons president chief executive officer yeah balaji thanks question regulatory process always nuance change highlighted believe cbm information need approval path believe technical section approved end june administrative process follow typically administrative process pretty straightforward adufa timeline noted day expect new dynamic relative trio market market growth highlighted get detail already disclosed relative quattro label believe broader coverage valued marketplace believe capability one broadest inside vet clinic outside vet clinic parasiticide capability globally give u great opportunity market desiring see shift thank questionkaty grissom head investor relation jeff send closejeff simmons president chief executive officer yeah quickly thank thanks interest elanco continue say inside company outside company three key driver company growth innovation cash believe quarter showed proof point really third quarter row third consecutive quarter nice solid growth diverse portfolio farm animal pet health yous international even price volume innovation side really want note existing innovation million quarter got nice momentum innovation increasing guide latestage highlight increased certainty proof point noted progress february todd mentioned inventory come networking capital gone cash conversion track aqua sale midyear also tracking ultimately think inside elanco engagement high energy executing quarter quarter delivered another quarter focus continue going forward keep anchoring back growth innovation cash thank time today look forward engaging throughout quarteroperatoroperator signoff duration minutescall participantskaty grissom head investor relationsjeff simmons president chief executive officertodd young chief financial officerjon block stifel financial corp analysterin wright morgan stanley analystmike ryskin bank america merrill lynch analystmike difiore evercore isi analystekaterina knyazkova jpmorgan chase company analystbrandon vazquez william blair company analystnate rich goldman sachs analystdave westenberg piper sandler analystchris lobianco td cowen analystnavann ty exane bnp paribas analystbalaji prasad barclays analyst elan analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy